BioCryst Pharmaceuticals reported its first full year of profitability in 2025 and posted $218.25 million in revenue for Q2 2026, a 33.6% increase year-over-year. The company, known for its rare disease drug Orladeyo, which generated $158.2 million in Q2 revenue, is attracting takeover speculation following its acquisition of Astria Therapeutics earlier in 2026. Potential strategic buyers include Takeda, AstraZeneca, and others, though private equity interest is lower due to BioCryst's debt and obligations. Investors are watching for upcoming data on navenibart, a promising injectable drug, and any acquisition moves.
Amgen announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Key executives Jay Bradner and Thomas Dittrich will discuss the company's research, development, artificial intelligence initiatives...
Novartis' failed cholesterol drug trial for pelacarsen caused a sharp 14% drop in its stock and dragged down the entire Lp(a) drug class, hitting Amgen hardest with a 10% decline despite Amgen's positive Phase 3 lung cancer trial results announced th...
Jim Cramer recommended buying Johnson & Johnson (JNJ) shares during a recent dip, citing upcoming data from the Psych Congress conference and strong sales growth. Despite a 2.33% drop in the session, JNJ has outperformed the market with a 53.76% gain...
Investment firm BMO Capital downgraded Amgen's stock from "Outperform" to "Market Perform" following a major clinical trial failure by Novartis for a similar cholesterol drug. Novartis' drug pelacarsen failed in a late-stage Phase III trial, casting ...
Amgen's Phase 3 DeLLphi-305 study demonstrated that IMDELLTRA (tarlatamab-dlle) combined with AstraZeneca's durvalumab significantly improves overall survival, progression-free survival, and response rates compared to durvalumab alone in patients wit...
